BPC157

 

 - BPC-157 is a synthetic peptide that is being investigated for its regenerative effects. It shows high efficacy for rats suffering toxic or surgical trauma, but there is currently 'no evidence that it provides benefits for people'.

https://examine.com/supplements/bpc-157/#sources-and-composition

 - BPC-157 is a peptide chain consisting of 15 amino acids.

 - It is considered synthetic because this particular sequence does not exist in nature. It is derived from a protective protein found in the stomach.

 - Researchers have conducted numerous rodent studies on BPC-157 that show it has protective effects extending beyond the stomach and intestinal tract.

 - BPC-157 has been shown to benefit ulcers in the stomach, intestinal damage such as fistulas and inflammatory disorders, bone and joint healing and growth rates, and organ damage. It also has some influences on the brain. Researchers have observed marked protective effects when BPC-157 is administered to rats alongside a research toxin or damaging surgical procedure.

 - More research is needed to clarify whether BPC-157 has multiple mechanisms of action, but current research suggests BPC-157 influences several growth factors usually involved in angiogenesis (the production of blood vessels) and other factors involved in regeneration following damage.

 - BPC-157 shows promise, but human studies are needed to demonstrate that these benefits extend beyond research animals.

 - The majority of studies on BPC-157 are done on rats given injections of the supplement. While BPC-157 is a stable peptide, peptides are a group of compounds that are normally poorly absorbed after oral supplementation, so researchers use injections in rodent studies instead. Furthermore, there is no human evidence for BPC-157 and the majority of the research has been conducted by a single research group.

 - Due to its synthetic nature, there may be legal issues associated with the sale of this supplement in certain regions and it may be banned by some sport organizations.

Neurosci Bull. 2019 Feb;35(1):167-170. doi: 10.1007/s12264-018-0269-8. Epub 2018 Aug 17.

Cytoprotective Mechanism of the Novel Gastric Peptide BPC157 in Gastrointestinal Tract and Cultured Enteric Neurons and Glial Cells.

Cell Tissue Res. 2019 Mar 27. doi: 10.1007/s00441-019-03016-8. [Epub ahead of print]

Gastric pentadecapeptide body protection compound BPC 157 and its role in accelerating musculoskeletal soft tissue healing.

Gwyer D1, Wragg NM2, Wilson SL3.

Author information

Abstract

There is a current need for a therapy that can alleviate the social and economic burden that presents itself with debilitating and recurring musculoskeletal soft tissue injuries and disorders. Currently, several therapies are emerging and undergoing trials in animal models; these focus on the manipulation and administration of several growth factors implicated with healing. However, limitations include in vivo instability, reliance on biocompatible and robust carriers and restricted application procedures (local and direct).

The aim of this paper is therefore to critically review the current literature surrounding the use of BPC 157, as a feasible therapy for healing and functional restoration of soft tissue damage, with a focus on tendon, ligament and skeletal muscle healing.

Currently, all studies investigating BPC 157 have demonstrated consistently positive and prompt healing effects for various injury types, both traumatic and systemic and for a plethora of soft tissues. However, to date, the majority of studies have been performed on small rodent models and the efficacy of BPC 157 is yet to be confirmed in humans. Further, over the past two decades, only a handful of research groups have performed in-depth studies regarding this peptide.

Despite this, it is apparent that BPC 157 has huge potential and following further development has promise as a therapy to conservatively treat or aid recovery in hypovascular and hypocellular soft tissues such as tendon and ligaments. Moreover, skeletal muscle injury models have suggested a beneficial effect not only for disturbances that occur as a result of direct trauma but also for systemic insults including hyperkalamia and hypermagnesia. Promisingly, there are few studies reporting any adverse reactions to the administration of BPC 157, although there is still a need to understand the precise healing mechanisms for this therapy to achieve clinical realisation.

Curr Pharm Des. 2018;24(18):1947-1956. doi: 10.2174/1381612824666180614082950.

BPC157 as Potential Agent Rescuing from Cancer Cachexia.

Kang EA1, Han YM1, An JM1, Park YJ2, Sikiric P3, Kim DH4, Kwon KA5, Kim YJ5, Yang D5, Tchah H5, Hahm KB1,4.

Author information

Abstract

Cancer cachexia, one of the metabolic syndromes caused by cancer, is a devastating and miserable condition encountered in more than 50% of terminal cancer patients presenting with significant weight loss associated with skeletal muscle atrophy and fat loss. Though cachexia may account for up to 20% of cancer deaths, no significant treatment is still lacking and is of urgent unmet medical need in cancer treatment. Therefore, understanding the underlying molecular mechanisms is essential for anticipating therapeutic approaches. Since the primary events driving cachexia are mediated via either the central nervous system related or inflammation related-anorexia, hypoanabolism, and hypercatabolism, therapy usually targets nutritional support to compensate reduced food intake along with some anti-inflammatory agents to cover specific inflammation-related metabolic derangement, and encourages exercise to supplement reduced physical activity, but all proven to be not so effective so far. Therefore, combination therapies such as a standard multi-modal package including an anorexic agent, megestrol acetate, and anti-inflammatory agent coupled with the development of potential novel therapeutics promise a new era in rescuing patients from cancer cachexia. In this review, we propose the potential application of BPC157, one of the active cytoprotective agents isolated from gastric juices for cancer cachexia. Before clinical trial, we introduced the evidence showing BPC157 rescued from cancer cachexia supported with explored mode of actions.

Curr Pharm Des. 2018;24(18):1972-1989. doi: 10.2174/1381612824666180712110447.

BPC 157 and Standard Angiogenic Growth Factors. Gastrointestinal Tract Healing, Lessons from Tendon, Ligament, Muscle and Bone Healing.

Seiwerth S1, Rucman R1, Turkovic B1, Sever M1, Klicek R1, Radic B1, Drmic D1, Stupnisek M1, Misic M1, Vuletic LB1, Pavlov KH1, Barisic I1, Kokot A1, Japjec M1, Blagaic AB1, Tvrdeic A1, Rokotov DS1, Vrcic H1, Staresinic M1, Sebecic B1, Sikiric P1.

Author information

Abstract

Commonly, the angiogenic growth factors signify healing. However, gastrointestinal ulceration is still poorly understood particularly with respect to a general pharmacological/pathophysiological role of various angiogenic growth factors implemented in growth factors wound healing concept. Thereby, we focused on the stable gastric pentadecapeptide BPC 157, a peptide given always alone vs. standard peptidergic angiogenic growth factors (EGF, FGF, VEGF), and numerous carriers.

Further, we reviewed how the gastrointestinal tract healing could be generally perceived (i) in terms of angiogenic growth factors, and/or (ii) through the healing of extragastrointestinal tissues healing, such as tendon, ligament, muscle and bone, and vice versa. Respected were the beneficial effects obtained with free peptides or peptides with different carriers; EGF, FGF, VEGF, and BPC 157, their presentation along with injuries, and a healing commonality, providing their implementation in both gastrointestinal ulcer healing and tendon, ligament, muscle and bone healing. Only BPC 157 was consistently effective in all of the models of acute/chronic injury of esophagus, stomach, duodenum and lower gastrointestinal tract, intraperitoneally, per-orally or locally. Unlike bFGF-, EGF-, VEGF-gastrointestinal tract studies demonstrating improved healing, most of the studies on tendon, muscle and bone injuries provide evidence of their (increased) presentation along with the various procedures used to produce beneficial effects, compared to fewer studies in vitro, while in vivo healing has a limited number of studies, commonly limited to local application, diverse healing evidence with diverse carriers and delivery systems. Contrary to this, BPC 157 - using same regimens like in gastrointestinal healing studies - improves tendon, ligament and bone healing, accurately implementing its own angiogenic effect in the healing. Thus, we claim that just BPC 157 represents in practice a pharmacological and pathophysiological role of various peptidergic growth factors.